Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB)

增强 UAB 区域生物防护实验室 (SEBLAB) 的科学发现和研究基础设施

• 批准号: 10626482
• 负责人: Sixto Manuel Leal
• 金额: $ 433万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626482
• 关键词: Accreditation; Alabama; Bioenergetics; Biomedical Research; Clinical; Containment; Cyclotrons; Development; Diagnostic; Diagnostic Imaging; Diagnostic tests; Disease Outbreaks; Equipment; Future; High Resolution Computed Tomography; In Vitro; Infrastructure; Investigation; Investments; Laboratories; Light; Microscope; Mission; Molecular; National Institute of Allergy and Infectious Disease; Output; Patient Care; Positron-Emission Tomography; Productivity; Public Health; Radioisotopes; Rapid diagnostics; Research; Research Infrastructure; Risk; Strategic Planning; Technology; Translating; Translational Research; Universities; Validation; biodefense; in vivo; innovation; new technology; noninvasive diagnosis; novel; pandemic disease; pandemic preparedness; pathogen; public health intervention; single cell sequencing; single photon emission computed tomography; ultra high resolution; Accreditation; Alabama; Bioenergetics; Biomedical Research; Clinical; Containment; Cyclotrons; Development; Diagnostic; Diagnostic Imaging; Diagnostic tests; Disease Outbreaks; Equipment; Future; High Resolution Computed Tomography; In Vitro; Infrastructure; Investigation; Investments; Laboratories; Light; Microscope; Mission; Molecular; National Institute of Allergy and Infectious Disease; Output; Patient Care; Positron-Emission Tomography; Productivity; Public Health; Radioisotopes; Rapid diagnostics; Research; Research Infrastructure; Risk; Strategic Planning; Technology; Translating; Translational Research; Universities; Validation; biodefense; in vivo; innovation; new technology; noninvasive diagnosis; novel; pandemic disease; pandemic preparedness; pathogen; public health intervention; single cell sequencing; single photon emission computed tomography; ultra high resolution

Project Summary: The current proposal outlines a strategic plan to implement novel technologies within containment that will advance the NIAID mission to support pandemic preparedness and biomedical research on risk group III (RGIII) pathogens. This proposal focuses on the implementation of cutting edge equipment to advance in vitro (Aim1), in vivo (Aim2), and molecular investigation (Aim3) of high containment pathogens and also seeks to build upon the diagnostic expertise of the Scientific Director to establish a high containment molecular infrastructure capable of rapidly responding to future emerging pandemic threats with rapid diagnostic test development and real-world implementation for patient care and public health intervention. Innovations include: 1) First proposal seeking to acquire cutting edge equipment to increase scientific productivity at University of Alabama at Birmingham (UAB)’s SEBLAB, 2) Novel use of the Zeiss lattice light-sheet microscope within containment, 3) Innovative implementation of ultra-high resolution computed tomography and PET/SPECT capabilities enabling use of novel radionuclides generated by the nation’s largest TR24 cyclotron (UAB) for non-invasive diagnostic imaging research on RGIII pathogens, 4) Create the ability to perform bioenergetic analyses and single cell sequencing at SEBLAB, and 5) Implement molecular infrastructure within containment enabling rapid diagnostic test development and validation with a clear path to implementation in CLIA/CAP-accredited clinical and public health laboratories. Given the current pandemic, risks for future outbreaks, and rapid advancement of research technologies, investment in the UAB SEBLAB as outlined in the current proposal will translate into real-world impacts on pandemic preparedness and accelerate hyper-competitive basic biomedical and translational research output that advances our basic understanding and biodefense capabilities against high containment pathogens.

项目摘要：当前提案概述了实施新颖的战略计划 遏制中的技术将推进NIAID任务以支持大流行 风险组III（RGIII）病原体的准备和生物医学研究。该提案重点是 关于实施尖端设备以在体外推进（AIM1），体内（AIM2）和 高遏制病原体的分子投资（AIM3），也试图建立在 科学主管的诊断专业知识，以建立高遏制分子 能够快速应对未来新兴大流行威胁的基础设施 诊断测试开发和针对患者护理和公共卫生的现实实施 干涉。创新包括：1）寻求获取最先进设备的首先提案 提高阿拉巴马大学伯明翰大学（UAB）的Seblab的科学生产力，2）小说 在围栏内使用Zeiss晶格灯页显微镜，3）创新实现 超高分辨率计算机断层扫描和宠物/镜头能力，可实现新颖 美国最大的TR24回旋子（UAB）生成的无创诊断诊断产生的放射性核素 对RGIII病原体的成像研究，4）创造能力进行生物能分析和 Seblab的单细胞测序和5）在围栏内实施分子基础架构 在以清晰的途径 CLIA/CAP认可的临床和公共卫生实验室。考虑到当前的大流行， 未来的爆发以及研究技术的快速发展，对UAB的投资 当前提案中概述的Seblab将转化为现实世界对大流行的影响 准备性和加速性竞争性基本生物医学和翻译研究 提高我们基本的理解和生物化功能的输出能力 遏制病原体。